Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plonmarlimab (Primary)
Indications COVID-19 respiratory infection; Cytokine release syndrome
Focus Therapeutic Use
Sponsors I-MAB Biopharma

Most Recent Events

31 Aug 2022 According to an I-mab Biopharma media release, the last patient out was in February 2022, and the final clinical study report is expected in the second half of 2022.
18 May 2022 Status changed from recruiting to completed.
11 Aug 2021 Interim results presented in an I-MAB Biopharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com